Pharmaceuticals
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Sanofi Yanks Obesity Drug Application
- Sanofi's Prospects Get Leaner
- Why Sanofi-Aventis Must Buy Bristol-Myers
- Serious Setback for Sanofi
- Sanofi Drug Has Suicide Risk
- Sanofi-Aventis Boosts Outlook
- Del.icio.us
- Digg
- StumbleUpon
The agency said doctors in the EU have been warned about possible psychiatric side effects for 13 months, adding that medical advisors have recommended "upgrading" this warning. "Psychiatric side effects, in particular depression, were identified as the main safety issue at the time of approval," the agency said. "They were reflected in the medicine's product information." Last month, European health regulators asked Sanofi-Aventis to provide "all available information" on psychiatric side effects. They concluded "the benefits of Acomplia continue to outweigh its risks, except in patients with ongoing major depression or taking antidepressants." Shares of Sanofi-Aventis were recently up 23 cents to $42.92.
Zimulti might be resubmitted.
The stock falls a day after an FDA panel says a weight-loss drug shouldn't be sold in the U.S.
Holding Bristol and waiting for the fireworks here might pay off.
An FDA panel says a weight-loss drug should be denied approval.
The FDA staff says Acomplia increases the chance of psychiatric problems.
First-quarter profits slip.
These forgotten Internet stocks are being accumulated by hedge funds.
Raspberries for Apple; You'll be sorry, UBS; Fortress or Fort Knox? Wholly unappetizing Foods; give Liberty AOL or give them...
The GOP presidential candidate raised $27 million in July.
Some credit and debit cards give you some cash back on purchases. But you need to manage it well to benefit from it.
Sponsored by:
RSS
